Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diva LaboratoriesROCO:4153 -1.88%74 PEG Ratio is 0.74 as of Jul. 15, 2026, which is 12% below its 10-year median of 0.84. GuruFocus rates ROCO:4153 with a GF Score™ of 74/100 and a GF Value™ of NT$38.03 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 36 Medical Diagnostics & Research companies, Diva Laboratories ranks better than 83.33% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Diva Laboratories's PEG Ratio or its related term are showing as below:
ROCO:4153'
s PEG Ratio Range Over the Past 10 Years
Min: 0.51 Med: 0.84 Max: 13.56
Current: 0.73
During the past 13 years, Diva Laboratories's highest PEG Ratio was 13.56. The lowest was 0.51. And the median was 0.84.
ROCO:4153's PEG Ratio is ranked better than 83.33% of 36
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.385
vs ROCO:4153: 0.73
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Diva Laboratories (ROCO:4153) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Diva Laboratories PEG Ratio Related Terms
Diva Laboratories PEG Ratio Historical Data
* Premium members only.
The historical data trend for Diva Laboratories's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Diva Laboratories's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diva Laboratories PEG Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Diva Laboratories's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Diva Laboratories (ROCO:4153) has a PEG Ratio of 0.74 as of Jul. 15, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Diva Laboratories and its competitors. This is 12% below median its historical median of 0.84. Over the past decade, Diva Laboratories' PEG Ratio has ranged from 0.51 to 13.56. According to the industry distribution chart, Diva Laboratories ranks #6 out of 36 companies in the Medical Diagnostics & Research industry, placing it in the top 16.7%.
Is Diva Laboratories' PEG Ratio too high?
Diva Laboratories' current PEG Ratio of 0.74 is 12% below median its 10-year median of 0.84. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 13.56. The Medical Diagnostics & Research industry median PEG Ratio is 2.39. Diva Laboratories' value of 0.74 is 69% below this industry median. Based on the distribution chart, Diva Laboratories ranks #6 out of 36 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Diva Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diva Laboratories' PEG Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diva Laboratories ranks #6 out of 36 companies for PEG Ratio. This places Diva Laboratories in the top 17% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 2.39. Diva Laboratories' value of 0.74 is 69% below this benchmark. Historically, Diva Laboratories' own PEG Ratio has ranged from 0.51 to 13.56 over the past decade. While the company's 10-year median is 0.84 vs. the industry median of 2.39, Diva Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Diagnostics & Research company?
The median PEG Ratio among Medical Diagnostics & Research companies is 2.39, based on 36 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diva Laboratories's current PEG Ratio of 0.74 is 69% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Diva Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median PEG Ratio is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diva Laboratories's current PEG Ratio is 0.74, which is 12% below median its own 10-year median of 0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diva Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Diva Laboratories (ROCO:4153) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.03, compared to a current price of NT$31.40 — trading 17.4% below its estimated fair value. The current PEG Ratio is 0.74, which is 12% below median its 10-year median of 0.84 and 69% below the Medical Diagnostics & Research industry median of 2.39. Diva Laboratories' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Diva Laboratories (ROCO:4153), the current PEG Ratio is 0.74 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diva Laboratories (ROCO:4153) Overvalued in 2026?
Based on GuruFocus' analysis, Diva Laboratories stock appears to be undervalued.
The current stock price of NT$31.40 is trading 17.4% below its estimated GF Value™ of NT$38.03.
GuruFocus considers Diva Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4153:
PEG Ratio: 0.74 (12% below median its 10-year median of 0.84)
GF Value™: NT$38.03 vs. price of NT$31.40 (17.4% below fair value)
Industry Position: 69% below the Medical Diagnostics & Research median (#6 of 36)
No single metric tells the full story. See the ROCO:4153 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diva Laboratories Ltd is engaged in the sale, manufacturing and development of medical equipment and computer-related devices. Its products are divided into Medical display which includes radiology, endo/surgical, touch, and embedded display; and Industrial display which includes touch display monitors. It derives revenue from sale of Medical monitors, Medical parts, Industrial monitors, Industrial parts, and Parts. Geographically it operates and derives revenue from Taiwan.
74GF Score
Get the complete analysis for ROCO:4153
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4153 has been successfully added to your 
